Pfizer’s Next-Generation ALK/ROS1 Inhibitor, Lorlatinib, Granted Breakthrough Therapy Designation from FDA for ALK-Positive Metastatic Non-Small Cell Lung Cancer | Pfizer Pharmaceutical News and Media | Pfizer: the world's largest research-based pharmaceutical company
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.